CDH1 and hepatocellular carcinoma: In contrast, defactinib only inhibited the activity of FAK and decreased pFAK level, but did not affect the expression of E-cadherin and vimentin in HCC cells, nor could it prevent EMT of HCC cells by inhibiting the phosphorylation of FAK (Figs. 4D and 4E).